Shandong Xinhua Pharmaceutical (SHE:000756, HKG:0719) obtained approval for the supplementary drug application for its phenobarbital tablets from China's National Medical Products Administration, according to a Monday Hong Kong bourse filing.
The approval came as the drug passed the regulator's consistency of quality and efficacy evaluation.
Phenobarbital tablets are mainly used to treat anxiety, insomnia, epilepsy, and grand mal and partial seizures.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments